1. Report Overview

1.1 Global Rheumatoid Arthritis Drugs Market Overview

1.2 Overview of Findings

1.3 Structure of the Report

1.4 Global Rheumatoid Arthritis Drugs Market Segmentation

1.5 Why You Should Read This Report

1.6 How This Report Delivers

1.7 Key Questions Answered by This Analytical Report

1.8. Who is This Report For?

1.9 Methodology

1.10 Associated Visiongain Reports

1.11 About Visiongain



2. Introduction to Rheumatoid Arthritis Drugs

2.1 What is Rheumatoid Arthritis?

2.2 What Causes Rheumatoid Arthritis?

2.3. How Does the Disease Develop?

2.4. How Can It Be Monitored?

2.5. Can RA Be Cured?

2.6. Performance Criteria Used in Clinical Trials

2.6.1. ACR Criteria for Drug Efficacy

2.6.2. HAQ-DI Measures Daily Activities

2.6.3. mSS Assesses Disease on X-Ray

2.6.4. DAS28 For Disease Severity

2.7. How is RA Treated?

2.7.1 Biologic DMARDs Are the Dominant Source of Revenue

2.7.2 Synthetic DMARDs are the Mainstay of Treatment

2.7.3 Others

2.7.3.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

2.7.3.2 Corticosteroids for Rapid Anti-Inflammatory Effect

2.7.3.3 Analgesics for Rapid Pain Relief

2.8 Comorbid Conditions Associated with RA

2.9 Prevalence and Incidence Rates of Rheumatoid Arthritis

3. Global Rheumatoid Arthritis Drugs Market by Drugs Class 2019-2029

3.1 The Global Rheumatoid Arthritis Drugs Market: Market Overview

3.2 Global Rheumatoid Arthritis Drugs Market: Revenue Forecast 2019-2029

3.3 Global Rheumatoid Arthritis Drugs Market: Market Forecast 2019-2029

3.4 Changing Market Shares by Segment 2019-2029

3.5 Non-Biologics Rheumatoid Arthritis Drugs Market

3.5.1 NSAIDs: Revenue Forecast, 2017-2029

3.5.2 Synthetic DMARDs (sDMARDs): Revenue Forecast, 2017-2029

3.5.3 Others: Revenue Forecast, 2017-2029

4. Leading Drugs in the Rheumatoid Arthritis Market 2019-2029

4.1 The Main Drugs in the Rheumatoid Arthritis Market, 2018

4.2 Humira: A Major Source of Revenue for AbbVie

4.2.1 Adalimumab Biosimilars

4.2.2 Humira: Sales Forecast 2019-2029

4.3 Enbrel: Amgen’s Revenue Protected Until 2029

4.3.1 Etanercept Biosimilars

4.3.2 Enbrel: Revenue Forecast 2017-2029

4.4 Remicade: Facing Significant Competition from Biosimilars

4.4.1 Infliximab Biosimilars

4.4.2 Remicade: Revenue Forecast 2017-2029

4.5 Rituxan: Facing Declining Market Share

4.5.1 Rituximab Biosimilars

4.5.2 Rituxan: Revenue Forecast 2017-2029

4.6 Simponi (golimumab): Market Share Remaining Stable

4.6.1 Simponi/Simponi Aria: Revenue Forecast 2017-2029

4.7 Orencia: Additional Indications Being Explored

4.7.1 Abatacept Biosimilars

4.7.2 Orencia: Revenue Forecast 2017-2029

4.8 Actemra/RoActemra: First IL-6R Inhibitor Approved for RA

4.8.1 Tocilizumab Biosimilars

4.8.2 Actemra/RoActemra: Revenue Forecast 2017-2029

4.9 Cimzia: Reliable Source of Income for UCB

4.9.1 Certolizumab Biosimilars

4.9.2 Cimzia: Revenue Forecast 2017-2029

4.10 Celebrex: Facing Generic Competition

4.10.1 Celebrex: Revenue Forecast 2017-2029

4.11 Xeljanz: Good Opportunity for Revenue Growth

4.11.1 Xeljanz: Revenue Forecast 2017-2029

4.12 Arcoxia: Sales Revenue Already Declining

4.12.1 Arcoxia: Revenue Forecast 2017-2029

5. Leading National Markets 2019-2029

5.1. Geographical Breakdown of the World Rheumatoid Arthritis Drugs Market

5.2 World Rheumatoid Arthritis Drugs Market: Regional Forecast 2019-2029

5.2.1 How Will Regional Market Shares Change to 2029?

6. North America Rheumatoid Arthritis Drugs Market 2019-2029

6.1. US Rheumatoid Arthritis Drugs Market: Market Forecast 2019-2029

6.2. Canada Rheumatoid Arthritis Drugs Market: Trends and Developments

7. Europe Rheumatoid Arthritis Drugs Market 2019-2029

7.1 Europe Markets: Changing Market Shares by Country, 2019-2029

7.2 German Rheumatoid Arthritis Drugs Market: Market Forecast 2019-2029

7.3 France Rheumatoid Arthritis Drugs Market Forecast 2019-2029

7.4. U.K. Rheumatoid Arthritis Drugs Market Forecast 2019-2029

7.5 Italy Rheumatoid Arthritis Drugs Market Forecast 2019-2029

7.6. Spain Rheumatoid Arthritis Drugs Market Forecast 2019-2029

7.7. Russia Rheumatoid Arthritis Drugs Market Forecast 2019-2029

7.8. Rest of Europe Rheumatoid Arthritis Drugs Market Forecast 2019-2029

8. Asia-Pacific Rheumatoid Arthritis Drugs Market 2019-2029

8.1 Chinese Rheumatoid Arthritis Drugs Market Forecast 2019-2029

8.2. Japanese Rheumatoid Arthritis Drugs Market Forecast 2019-2029

8.3. Indian Rheumatoid Arthritis Drugs Market Forecast 2019-2029

8.4. Rest of Asia-Pacific Rheumatoid Arthritis Drugs Market: Trends and Developments

9. Latin America Rheumatoid Arthritis Drugs Market 2019-2029

9.1 Brazil Rheumatoid Arthritis Drugs Market Forecast 2019-2029

9.2. Mexico Rheumatoid Arthritis Drugs Market Forecast 2019-2029

9.3. Rest of Latin America Rheumatoid Arthritis Drugs Market Forecast 2019-2029

10. Middle East & Africa Rheumatoid Arthritis Drugs Market 2019-2029

10.1. Saudi Arabia Rheumatoid Arthritis Drugs Market Forecast 2019-2029

10.2. South Africa Rheumatoid Arthritis Drugs Market Forecast 2019-2029

10.3. Rest of Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast 2019-2029

11. Rheumatoid Arthritis R&D Pipeline 2018

11.1 IL-6 Inhibitors Could Rival TNF-Inhibitors

11.1.1 Sarilumab: Already Filed With FDA

11.1.2 Sirukumab: Expected to File in Q3, 2016

11.1.3 Olokizumab: Promising Phase 2 Data

11.1.4 Clazakizumab

11.2 JAK Inhibitors: A Promising Class of Agents

11.2.1 Peficitinib: Selective JAK-3 Inhibitor from Astellas

11.2.2 ABT-494: Selective JAK-1 Inhibitor from AbbVie

11.2.3 Filgotinib: Following AbbVie’s Withdrawal, Galapagos Now Working with Gilead

11.3 BTK Inhibitors

11.3.1 BMS-986142

11.3.2 HM71224

11.4 GM-CSF Inhibitor

11.4.1 GSK 3196165: Potential Role in Early Disease

12. Leading Companies in the Rheumatoid Arthritis Drugs Market, 2017

12.1 Introduction to the Leading Companies

12.2. AbbVie: Secured Multiple Patents for Humira

12.2.1 Overview

12.2.2 Financial Overview

12.2.3. Recent Transactions Summary

12.3. F. Hoffmann-La Roche Ltd (Roche)

12.3.1 Overview

12.3.2 Financial Overview

12.3.3. Recent Transactions Summary

12.4. Johnson & Johnson

12.4.1 Overview

12.4.2 Financial Overview

12.4.3. Recent Transactions Summary

12.5. Amgen, Inc.

12.5.1 Overview

12.5.2 Financial Overview

12.5.3.Recent Transactions Summary

12.6. Pfizer: Actively Developing Biosimilars

12.6.1 Overview

12.6.2 Pfizer, Inc.: Financial Overview

12.6.3 Pfizer, Inc.: Recent Developments

12.7. Merck & Co., Inc.: Remicade Sales in Decline

12.7.1. Overview

12.7.2 Merck & Co., Inc.: Financial Overview

12.7.3 Merck & Co., Inc.: Recent Transactions Summary

12.8. Bristol-Myers Squibb (BMS): Exploring Additional Indications for Orencia

12.8.1. Overview

12.8.2 Bristol-Myers Squibb: Financial Overview

12.8.3 Bristol-Myers Squibb: Recent Developments

12.9 UCB: Reliant on Cimzia Revenue

12.9.1 Overview

12.9.2 UCB: Financial Overview

12.9.3 UCB: Recent Transactions Summary

12.10 Eli Lilly and Company

12.10.1 Eli Lilly and Company: RA Drugs Portfolio

12.10.2 Eli Lilly and Company: Financial Overview

12.10.3 Eli Lilly and Company: Recent Transactions Summary

12.11 Novartis AG

12.11.1 Novartis: Rheumatoid Arthritis Drugs Product Portfolio

12.11.2 Novartis AG: Financial Overview

12.11.3 Novartis AG: Recent Transactions Summary

12.12 Sanofi S.A. (Sanofi)

12.12.1 Sanofi: Rheumatoid Arthritis Drugs Portfolio

12.12.2 Sanofi: Financial Overview

12.12.3 Sanofi: Recent Transactions Summary

13. Qualitative Analysis of the Rheumatoid Arthritis Market, 2019-2029

13.1 Strengths and Weaknesses of the Rheumatoid Arthritis Market, 2017

13.1.1 Strengths

13.1.1.1 Number of Elderly Patients Expected to Rise

13.1.1.2 Biologics Already Recognised as a Valuable Part of Treatment

13.1.1.3 Biologics Used in RA Often Have Multiple Indications

13.1.2 Weaknesses

13.1.2.1 Some Patients Have an Inadequate Treatment Response

13.1.2.2. Efficacy of Drugs Can Diminish Over Time

13.1.3. Opportunities

13.1.3.1 Need for Effective Drugs with Better Safety Profiles

13.1.3.2 Need for Less Invasive Routes of Administration

13.1.4. Threats

13.1.4.1 High Number of Products Will Saturate Market

13.1.4.2 Competition from Biosimilars Will Increase

13.2 Social, Technological, Economic and Political Factors Affecting the Rheumatoid Arthritis Market (STEP Analysis), 2019-2029

13.2.1 Social Factors Influencing the Rheumatoid Arthritis Market

13.2.2 Technological Factors Influencing the Rheumatoid Arthritis Market

13.2.3 Economic Factors Influencing the Rheumatoid Arthritis Market

13.2.4 Political Factors Influencing the Rheumatoid Arthritis Market

13.2.4.1 Government Pressure to Control Costs

13.2.4.2 Inter-country Variability in Biosimilar Approval Process

14. Conclusions

14.1 Overview of Current Market Conditions and Market Forecast, 2019-2029

14.2 Biologics Will Remain the Dominant Drug Class but their Market Share Will Drop By More than 20%

14.3 Enbrel Will Overtake Humira as the Leading Drug

14.4 Leading Regions in the Rheumatoid Arthritis Market in 2017

14.5 Trends in the RA Drugs Market

Appendices

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain Report Evaluation Form

List of Tables

Table 2.1 Biologic Agents and Mechanism of Action

Table 2.2 Comorbidities Associated with RA in Different Organs

Table 2.3 Prevalence rate of RA in Different Countries

Table 3.1 Rheumatoid Arthritis Drugs Market by Submarket, 2017

Table 3.2 Global Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029

Table 3.3 Global Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029

Table 3.4 Global Rheumatoid Arthritis Drugs Market by Drugs Class: CAGR (%), 2019-2023, 2023-2029, 2019-2029

Table 3.5 Global Non- Biologics Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029

Table 3.6 NSAIDs for Rheumatoid Arthritis Forecasts: Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 3.7 sDMARDs for Rheumatoid Arthritis Forecasts: Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 3.8 Others for Rheumatoid Arthritis Forecasts: Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 4.1 Global Rheumatoid Arthritis Market by Drugs Class: Revenue ($m), and Market Share (%), 2018

Table 4.2 The Main Drugs in the Rheumatoid Arthritis Market Forecasts: Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 4.2 The Main Drugs in the Rheumatoid Arthritis Market Forecasts: Revenue ($m), AGR (%) and CAGR (%), 2017-2029 - Cont.

Table 4.3 Humira: Key Facts

Table 4.4 Adalimumab Biosimilars: Current Status, 2018

Table 4.5 Global Humira Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2017-2029

Table 4.6 Enbrel: Key Facts

Table 4.7 Etanercept Biosimilars: Current Status, 2018

Table 4.8 Global Enbrel Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2017-2029

Table 4.9 Remicade: Key Facts

Table 4.10 Infliximab Biosimilars: Current Status, 2018

Table 4.11 Global Remicade Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2017-2029

Table 4.12 Rituxan: Key Facts

Table 4.13 Rituximab Biosimilars: Current Status, 2018

Table 4.14 Global Rituxan Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2017-2029

Table 4.15 Simponi: Key Facts

Table 4.16 Global Simponi/Simponi Aria Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2017-2029

Table 4.17 Orencia: Key Facts

Table 4.18 Global Orencia Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2017-2029

Table 4.19 Actemra/RoActemra: Key Facts

Table 4.20 Global Actemra/RoActemra Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2017-2029

Table 4.21 Cimzia: Key Facts

Table 4.22 Global Cimzia Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2017-2029

Table 4.23 Celebrex: Key Facts

Table 4.24 Global Celebrex Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2017-2029

Table 4.25 Xeljanz: Key Facts

Table 4.26 Global Xeljanz Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2017-2029

Table 4.27 Arcoxia: Key Facts

Table 4.28 Global Arcoxia Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2017-2029

Table 5.1 Global Rheumatoid Arthritis Drugs Market by Region: Revenue ($m), 2017 and 2018

Table 5.2 Global Rheumatoid Arthritis Drugs Market Forecast by Region: Revenues ($m), AGR (%), CAGR (%), 2017-2029

Table 5.3 Global Rheumatoid Arthritis Drugs Market by Region: CAGR (%), 2019-2023, 2023-2029, 2019-2029

Table 5.4 Global Rheumatoid Arthritis Drugs Market by Region: CAGR (%), 2019-2023, 2023-2029, 2019-2029

Table 6.1 North America Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues ($m), AGR (%), CAGR (%), 2017-2029

Table 6.2 North America Rheumatoid Arthritis Drugs (Non-Biologics) Market Forecast by Segment: Revenues ($m), AGR (%), CAGR (%), 2017-2029

Table 6.3 North America Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2017-2029

Table 6.4 U.S. Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029

Table 6.5 Canada Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029

Table 7.1 Global Rheumatoid Arthritis Drugs Market by Country/Sub-region: Revenue ($m) and Market Share (%), 2017

Table 7.2 Europe Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues ($m), AGR (%), CAGR (%), 2017-2029

Table 7.3 Europe Rheumatoid Arthritis Drugs (Non-Biologics) Market Forecast by Segment: Revenues ($ m), AGR (%), CAGR (%), 2017-2029

Table 7.4 Europe Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2017-2029

Table 7.5 Europe Rheumatoid Arthritis Drugs Market by Country/Sub-region: CAGR (%), 2019-2023, 2023-2029, 2019-2029

Table 7.6 Germany Rheumatoid Arthritis Drugs Market Forecast, 2017-2029 ($m, AGR %, CAGR %)

Table 7.7 France Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029

Table 7.8 U.K. Rheumatoid Arthritis Drugs Market Forecast, 2017-2029 ($m, AGR %, CAGR %)

Table 7.9 Italy Rheumatoid Arthritis Drugs Market Forecast, 2017-2029 ($m, AGR %, CAGR %)

Table 7.10 Spain Rheumatoid Arthritis Drugs Market Forecast, 2017-2029 ($m, AGR %, CAGR %)

Table 7.11 Russia Rheumatoid Arthritis Drugs Market Forecast, 2017-2029 ($m, AGR %, CAGR %)

Table 7.12 Rest of Europe Rheumatoid Arthritis Drugs Market Forecast, 2017-2029 ($m, AGR %, CAGR %)

Table 8.1 Asia-Pacific Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues ($m), AGR (%), CAGR (%), 2017-2029

Table 8.2 Asia-Pacific Rheumatoid Arthritis Drugs (Non-Biologics) Market Forecast by Segment: Revenues ($m), AGR (%), CAGR (%), 2017-2029

Table 8.3 Asia-Pacific Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2017-2029

Table 8.4 China Rheumatoid Arthritis Drugs Market Forecast, 2017-2029 ($m, AGR %, CAGR %)

Table 8.5 Japan Rheumatoid Arthritis Drugs Market Forecast, 2017-2029 ($m, AGR %, CAGR %)

Table 8.6 India Rheumatoid Arthritis Drugs Market Forecast, 2017-2029 ($m, AGR %, CAGR %)

Table 8.7 Rest of Asia Pacific Rheumatoid Arthritis Drugs Market Forecast, 2017-2029 ($m, AGR %, CAGR %)

Table 9.1 Latin America Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues ($m), AGR (%), CAGR (%), 2017-2029

Table 9.2 Latin America Rheumatoid Arthritis Drugs (Non-Biologics) Market Forecast by Segment: Revenues ($m), AGR (%), CAGR (%), 2017-2029

Table 9.3 Latin America Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2017-2029

Table 9.4 Brazil Rheumatoid Arthritis Drugs Market Forecast, 2017-2029 ($ m, AGR %, CAGR %)

Table 9.5 Mexico Rheumatoid Arthritis Drugs Market Forecast, 2017-2029 ($m, AGR %, CAGR %)

Table 9.6 Rest of Latin America Rheumatoid Arthritis Drugs Market Forecast, 2017-2029 ($m, AGR %, CAGR %)

Table 10.1 Middle East and Africa Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues ($m), AGR (%), CAGR (%), 2017-2029

Table 10.2 Middle East and Africa Rheumatoid Arthritis Drugs (Non-Biologics) Market Forecast by Segment: Revenues ($ m), AGR (%), CAGR (%), 2017-2029

Table 10.3 Middle East & Africa (MEA) Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2017-2029

Table 10.4 Saudi Arabia Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029

Table 10.5 South Africa Rheumatoid Arthritis Drugs Market Forecast, 2017-2029 ($m, AGR %, CAGR %)

Table 10.6 Rest of MEA Rheumatoid Arthritis Drugs Market Forecast, 2017-2029 ($m, AGR %, CAGR %)

Table 11.1 Pipeline R&D Products, 2018

Table 12.1 Leading Companies in the RA Drug Market: Revenue ($m) and Market Share (%), 2017

Table 12.2 AbbVie: Breakdown of Revenue ($m,%) by RA Drug, 2016

Table 12.3 AbbVie: Overview, 2018

Table 12.4 AbbVie: Revenue ($m), AGR (%), 2013-2017

Table 12.5 F.Hoffmann-La Roche AG: Breakdown of Revenue ($m,%) by RA Drug, 2017

Table 12.6. Roche: Overview, 2018

Table 12.7 Roche: Revenue ($m), AGR (%), 2013-2017

Table 12.8 Johnson & Johnson: Breakdown of Revenue ($m,%) by RA Drug, 2017

Table 12.9. Johnson & Johnson: Overview, 2018

Table 12.10 Johnson & Johnson: Revenue ($m), AGR (%), 2013-2017

Table 12.11 Amgen: Breakdown of Revenue ($m,%) by RA Drug, 2017

Table 12.12 Amgen, Inc.: Overview, 2018

Table 12.13 Amgen, Inc.: Revenue ($m), AGR (%), 2013-2017

Table 12.14 Pfizer, Inc.: Breakdown of Revenue ($m,%) by RA Drug, 2017

Table 12.15 Pfizer, Inc.: Overview, 2018

Table 12.16 Pfizer, Inc.: Revenue ($m), AGR (%), 2013-2017

Table 12.17 Merck & Co., Inc.: Breakdown of Revenue ($m,%) by RA Drug, 2017

Table 12.18 Merck & Co., Inc.: Overview, 2018

Table 12.19 Merck & Co., Inc.: Revenue ($m), AGR (%), 2013-2017

Table 12.20 Bristol-Myers Squibb: Breakdown of Revenue ($m,%) by RA Drug, 2017

Table 12.21 Bristol-Myers Squibb: Overview, 2017

Table 12.22 Bristol-Myers Squibb: Revenue ($m), AGR (%), 2013-2017

Table 12.23 UCB: Breakdown of Revenue ($m,%) by RA Drug, 2017

Table 12.24 UCB: Overview, 2018

Table 12.25 UCB: Revenue ($m), AGR (%), 2013-2017

Table 12.26 Eli Lilly and Company: Overview, 2018

Table 12.27 Eli Lilly and Company: Revenue ($m), AGR (%), 2013-2017

Table 12.28 Novartis AG: Overview, 2018

Table 12.29 Novartis AG: Revenue ($m), AGR (%), 2013-2017

Table 12.30 Sanofi: Overview, 2018

Table 12.31 Sanofi: Revenue ($m), AGR (%), 2013-2017

Table 13.1 SWOT Analysis of the Global Rheumatoid Arthritis Market, 2019-2029

Table 13.2 Social, Technological, Economic and Political Factors Influencing the RA Market, 2017-2029

Table 14.1 Global Rheumatoid Arthritis Market Forecast: Revenue ($m), and CAGR (%), 2017, 2023 and 2029

Table 14.2 Global Rheumatoid Arthritis Market by Drugs Class: CAGR (%), 2017, 2023, 2029

Table 14.3 Global Rheumatoid Arthritis Market by Region: CAGR (%), 2017, 2023, 2029

Table 14.4 Drivers and Restraints of the RA Drugs Market, 2019-2029

List of Figures

Figure 1.1 Global Rheumatoid Arthritis Drugs Market Segmentation Overview

Figure 3.1 Rheumatoid Arthritis Drugs Market: Market Share (%) by Indication, 2017

Figure 3.2 Rheumatoid Arthritis Drugs Market: Market Share (%) by Class, 2017

Figure 3.3 Global Rheumatoid Arthritis Drugs Market Forecast: Revenue ($m), AGR (%), 2017-2029

Figure 3.4 Global Rheumatoid Arthritis Drugs Market Revenues by Drug Class, 2018

Figure 3.5 Global Rheumatoid Arthritis Drugs Market Revenues by Drugs Class, 2019

Figure 3.6 Global Rheumatoid Arthritis Drugs Market Forecast by Drugs Class: CAGR (%), 2019-2029

Figure 3.7 Rheumatoid Arthritis Drugs Market Segments: Revenue ($m) Forecast, 2017-2029

Figure 3.8 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2018

Figure 3.9 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2023

Figure 3.10 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2029

Figure 3.11 Global Non-Biologics Rheumatoid Arthritis Drugs: Revenue ($m) Forecasts by Segment, 2017-2029

Figure 3.12 Global Non-Biologics Rheumatoid Arthritis Drugs Market by Segment: Share (%), 2018

Figure 3.13 Global Non-Biologics Rheumatoid Arthritis Drugs Market by Segment: Share (%), 2023

Figure 3.14 Global Non-Biologics Rheumatoid Arthritis Drugs Market by Segment: Share (%), 2029

Figure 3.15 NSAIDs for Rheumatoid Arthritis Market Forecast: Revenue ($m), AGR (%), 2017-2029

Figure 3.16 sDMARDs for Rheumatoid Arthritis Forecast: Revenue ($m), AGR (%), 2017-2029

Figure 3.17 Others Drugs Market Forecast: Revenue ($ m), AGR (%), 2017-2029

Figure 4.1 The Main Drugs in the Rheumatoid Arthritis Market: Market Shares (%), 2018

Figure 4.2 Global Humira Market Forecast: Revenue ($m) AGR (%), 2017-2029

Figure 4.3 Global Enbrel Market Forecast: Revenue ($m) AGR (%), 2017-2029

Figure 4.4 Global Remicade Market Forecast: Revenue ($m) AGR (%), 2017-2029

Figure 4.5 Global Rituxan Market Forecast: Revenue ($m) AGR (%), 2017-2029

Figure 4.6 Global Simponi/Simponi Aria Market Forecast: Revenue ($m) AGR (%), 2017-2029

Figure 4.7 Global Orencia Market Forecast: Revenue ($m) AGR (%), 2017-2029

Figure 4.8 Global Actemra/RoActemra Market Forecast: Revenue ($m) AGR (%), 2017-2029

Figure 4.9 Global Cimzia Market Forecast: Revenue ($m) AGR (%), 2017-2029

Figure 4.10 Global Celebrex Market Forecast: Revenue ($m) AGR (%), 2017-2029

Figure 4.11 Global Xeljanz Market Forecast: Revenue ($m) AGR (%), 2017-2029

Figure 4.12 Global Arcoxia Market Forecast: Revenue ($m) AGR (%), 2017-2029

Figure 5.1 World Rheumatoid Arthritis Drugs Market: Revenues ($m) by Region, 2017

Figure 5.2 World Rheumatoid Arthritis Drugs Market: Revenues ($m) by Region, 2018

Figure 5.3 Global Rheumatoid Arthritis Drugs Market Forecast: Revenue ($m), AGR (%), 2017-2029

Figure 5.4 Rheumatoid Arthritis Drugs Market: Market Shares (%) by Regional Market, 2017

Figure 5.5 Rheumatoid Arthritis Drugs Market: Market Shares (%) by Regional Market, 2023

Figure 5.6 Rheumatoid Arthritis Drugs Market: Market Shares (%) by Regional Market, 2029

Figure 6.1 North America Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 6.2 North America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2017

Figure 6.3 North America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2023

Figure 6.4 North America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2029

Figure 6.5 U.S. Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 6.6 Canada Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 7.1 Europe Rheumatoid Arthritis Drugs Market: Revenues ($m) by Country/Sub-region, 2017

Figure 7.2 Europe Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 7.3 Europe Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2017

Figure 7.4 Europe Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2023

Figure 7.5 Europe Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2029

Figure 7.6 Germany Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 7.7 France Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 7.8 U.K. Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 7.9 Italy Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 7.10 Spain Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 7.11 Russia Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 7.12 Rest of Europe Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 8.1 Asia-Pacific Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 8.2 Asia-Pacific Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2017

Figure 8.3 Asia-Pacific Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2023

Figure 8.4 Asia-Pacific Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2029

Figure 8.5 China Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 8.6 Japan Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 8.7 India Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 8.8 Rest of Asia Pacific Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 9.1 Latin America Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 9.2 Latin America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2017

Figure 9.3 Latin America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2023

Figure 9.4 Latin America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2029

Figure 9.5 Brazil Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 9.6 Mexico Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 9.7 Rest of Latin America Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 10.1 Middle East & Africa (MEA) Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 10.2 Middle East & Africa Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2017

Figure 10.3 Middle East & Africa Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2023

Figure 10.4 Middle East & Africa Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2029

Figure 10.5 Saudi Arabia Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 10.6 South Africa Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 10.7 Rest of MEA Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2017-2029

Figure 12.1 AbbVie: Revenue ($m), AGR (%), 2013-2017

Figure 12.2 AbbVie: Business Segment Revenue Share (%), 2017

Figure 12.3 AbbVie: Region Revenue Share (%), 2017

Figure 12.4 Roche: Revenue ($m), AGR (%), 2013-2017

Figure 12.5 Roche: Business Segment Revenue Share (%), 2017

Figure 12.6 Roche: Breakdown of Revenue (%) by Pharmaceuticals Drug, 2017

Figure 12.7 Johnson & Johnson: Revenue ($m), AGR (%), 2013-2017

Figure 12.8 Johnson & Johnson: Business Segment Revenue Share (%), 2017

Figure 12.9 Johnson & Johnson: Region Revenue Share (%), 2017

Figure 12.10 Amgen, Inc.: Revenue ($m), AGR (%), 2013-2017

Figure 12.11 Amgen, Inc.: Revenue by Division, Share (%), 2017

Figure 12.12 Amgen, Inc.: Revenue by Region, Share (%), 2017

Figure 12.13 Pfizer, Inc.: Revenue ($m), AGR (%), 2013-2017

Figure 12.14 Pfizer, Inc.: Business Segment Revenue Share (%), 2017

Figure 12.15 Pfizer, Inc.: National Revenue Share (%), 2017

Figure 12.16 Merck & Co., Inc.: Revenue ($m), AGR (%), 2013-2017

Figure 12.17 Merck & Co., Inc.: Business Segment Revenue Share (%), 2017

Figure 12.18 Merck & Co., Inc.: Region Revenue Share (%), 2017

Figure 12.19 Bristol-Myers Squibb: Revenue ($m), AGR (%), 2013-2017

Figure 12.20 Bristol-Myers Squibb: Segment Revenue Share (%), 2017

Figure 12.21 Bristol-Myers Squibb: National Revenue Share (%), 2017

Figure 12.22 UCB: Revenue ($m), AGR (%), 2013-2017

Figure 12.23 UCB: Business Segment Revenue Share (%), 2017

Figure 12.24 UCB: by Region Revenue Share (%), 2017

Figure 12.25 Eli Lilly and Company: Revenue ($m), AGR (%), 2013-2017

Figure 12.26 Eli Lilly and Company: Business Segment Revenue Share (%), 2017

Figure 12.27 Eli Lilly and Company: by Region Revenue Share (%), 2017

Figure 12.28 Novartis AG: Revenue ($m), AGR (%), 2013-2017

Figure 12.29 Novartis AG: Business Segment Revenue Share (%), 2017

Figure 12.30 Novartis AG: by Region Revenue Share (%), 2017

Figure 12.31 Sanofi: Revenue ($m), AGR (%), 2013-2017

Figure 12.32 Sanofi: Business Segment Revenue Share (%), 2017

Figure 12.33 Sanofi: Region Revenue Share (%), 2017

Figure 14.1 RA Drugs Market: Comparison of Revenue ($m Forecasts for Total Market* and Market for RA Indication, 2017-2029

Figure 14.2 Global Rheumatoid Arthritis Market Forecast: Revenue ($m) 2017, 2023, 2029

Figure 14.3 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2018

Figure 14.4 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2023

Figure 14.5 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2029

Figure 14.6 The Leading Drugs in the RA Market: Revenue ($m) Forecasts, 2017, 2023, 2029

Figure 14.7 The Global Rheumatoid Arthritis Market Forecast by Region: Revenue ($m), 2017, 2023, 2029